0.1960SEK-4.39%Mkt Cap: 123.11M SEKP/E: —Last update: 2026-06-01
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40,…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap123.11M SEK
Enterprise Value128.16M SEK
Revenue (TTM)520.00K SEK
Gross Profit-60.09M SEK
Net Income (TTM)-51.35M SEK
Revenue/Share0.0030 SEK
Last Price0.1960 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees11
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.56
PEG—
EV/EBITDA-1.54
EV/Revenue246.47
P/S247.62
P/B3.11
EPS (TTM)-1.33
EPS (Forward)-0.08
52W Range
0.15701% of range7.210
52W High7.210 SEK
52W Low0.1570 SEK
Profitability
Gross Margin0.00%
Oper. Margin-18215.31%
EBITDA Margin0.00%
Profit Margin-9990.27%
ROE-748.65%
ROA-46.43%
Growth
Revenue Growth-69.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-155.99M SEK
CapEx (TTM)1.46M SEK
FCF Margin-36347.52%
FCF Yield-153.53%
Net Debt-597.00K SEK
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity6.29
Current Ratio1.76
Quick Ratio1.21
Book Value/Sh0.0660 SEK
Cash/Share0.0530 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateApr 7, 2025
Analyst Consensus
Rating—
Target (Mean)0.3000 SEK
Target Range0.3000 SEK – 0.3000 SEK
# Analysts1
Ownership
Shares Out.628.11M
Float613.86M
Insiders16.45%
Institutions2.27%
Technical
SMA 500.2129 (-7.9%)
SMA 2001.277 (-84.7%)
Beta1.24
S&P 52W Chg27.70%
Avg Vol (30d)17.52M
Avg Vol (10d)4.85M
Technical Indicators
RSI (14)45.6
MACD-0.0045
MACD Signal-0.0029
MACD Hist.-0.0016
BB Upper0.2265 SEK
BB Middle0.2125 SEK
BB Lower0.1986 SEK
BB Width13.14%
ATR (14)0.0222 SEK
Vol Ratio (20d)0.39x